6/1/2011

New York-based Albany Molecular Research announced Tuesday that the firm's obesity compound ALB-127158(a) was safe and well tolerated among overweight participants in an early-stage trial. Experts noted reduced hunger, food cravings and meal consumptions in those who took the drug.

Full Story:
RTT News

Related Summaries